Cytokinetics, Inc. (CYTK) CEO Robert I. Blum Sells 4,000 Shares
Cytokinetics, Inc. (NASDAQ:CYTK) CEO Robert I. Blum sold 4,000 shares of the stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $7.94, for a total value of $31,760.00. Following the completion of the transaction, the chief executive officer now directly owns 164,022 shares in the company, valued at approximately $1,302,334.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ CYTK traded down $0.20 during midday trading on Friday, hitting $7.85. 189,225 shares of the company traded hands, compared to its average volume of 218,209. The company has a current ratio of 8.95, a quick ratio of 8.95 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $439.76 million, a PE ratio of -3.03 and a beta of 1.31. Cytokinetics, Inc. has a 52 week low of $6.20 and a 52 week high of $15.95.
Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, July 26th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.51). The company had revenue of $6.22 million for the quarter, compared to the consensus estimate of $5.54 million. equities analysts predict that Cytokinetics, Inc. will post -1.96 earnings per share for the current fiscal year.
Several research analysts recently issued reports on the company. BidaskClub raised Cytokinetics from a “hold” rating to a “buy” rating in a research note on Saturday. ValuEngine raised Cytokinetics from a “sell” rating to a “hold” rating in a research note on Thursday, August 23rd. Morgan Stanley cut Cytokinetics from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $18.00 to $9.00 in a research note on Wednesday, August 1st. HC Wainwright set a $24.00 price objective on Cytokinetics and gave the stock a “buy” rating in a research note on Friday, July 27th. Finally, Zacks Investment Research cut Cytokinetics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $14.00.
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Featured Article: What does EPS mean?
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.